Evaxion Biotech (EVAX) Provides Shareholder Update

Go back to Evaxion Biotech (EVAX) Provides Shareholder Update

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

July 3, 2024 8:05 AM UTC

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion or the Company), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today issued the following letter to shareholders.

Dear Fellow Shareholders of Evaxion,

The first half of 2024 has been off to a very productive start to the year for Evaxion. We have launched our refined strategy, and we are well positioned for value realization via our three-pronged business model focusing on vaccine target discovery collaborations using our core AI-Immunology platform (Targets),... More